Market Overview:

The companion diagnostics market is experiencing rapid growth, driven by rising adoption of precision medicine, surge in targeted therapy approvals and advancements in genomic technologies. According to IMARC Group’s latest research publication, “Companion Diagnostics Market Report by Product & Service (Assays, Kits and Reagents, Software and Services), Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, and Others), Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and Others), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, and Others), and Region 2025-2033.” The global companion diagnostics market size reached USD 7.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.11% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Grab a sample PDF of this report: https://www.imarcgroup.com/companion-diagnostics-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Companion Diagnostics Market

• Rising Adoption of Precision Medicine:

The increasing trend toward precision medicine is one of the main drivers of a growing companion diagnostics market. AS a global healthcare system moves away from the “one-size-fits-all” strategy to disease-targeted therapies designed uniquely to the individual’s genetic characteristics, lifestyle and environment. Companion diagnostics provides a medium which allows clinicians to select a particular treatment based on a patient’s biomarker profile. For instance, with oncology, the HER2 test for breast cancer will inform a physician whether a drug like trastuzumab will be appropriate for a patient with HER2-positive breast cancer. As familiarity with and access to such technologies expand in developed nations, companion diagnostic usage is likely to continue to grow.

• Surge in Targeted Therapy Approvals:

In the area of market expansion, there is also growth in the increasingly numerous approved targeted therapies by FDA/EMA and other regulatory authorities. Often the targeted therapy must be paired with a companion diagnostic approved at the same time to find appropriate patients. For example, osimeritinib, a drug for non-small cell lung cancer, requires testing for an EGFR mutation before beginning treatment with the drug. The requirement for the drug and a diagnostic to be approved at the same time is driving pharmaceutical companies to invest in the co-development strategy of a therapy and a diagnostic from the beginning. This co-development strategy ensures that both the therapy and diagnostic are moving toward approval at the same time. Co-development will also increase the likelihood of better patient outcomes, which is creating competitive demand for better diagnostics.

• Advancements in Genomic Technologies:

Improved accuracy and reliability of companion diagnostics have been made possible by rapid advances in technology, specifically in the area of genomics and molecular diagnostics. In particular, next-generation sequencing (NGS) allows for the simultaneous analysis of an individual’s multiple genes and provides a comprehensive molecular profile of the patient. This is advantageous when testing for complex conditions that may involve several genomic mutations, as is often the case with cancers. Technology has improved the reliability of, and decreased the time from, diagnosis to treatment. Likewise, reduced cost and improved access to these technologies has enabled their use in both research and clinical settings that will continue the expansion of the companion diagnostics market worldwide.

The companion diagnostics market report provides a comprehensive overview of the industry. This analysis is essential for stakeholders aiming to navigate the complexities of the biochar market and capitalize on emerging opportunities.

Key Trends in the Companion Diagnostics Market

• Integration of Artificial Intelligence in Diagnostics:

Artificial Intelligence (AI) is rapidly transforming the healthcare landscape, and its integration into companion diagnostics is a significant emerging trend. AI can process large datasets and identify patterns that may not be visible through traditional methods, leading to quicker and more accurate diagnoses. In the context of companion diagnostics, AI-powered platforms can predict patient response to specific treatments, optimize biomarker selection, and even personalize therapeutic approaches. For example, companies are developing AI-driven tools to support oncology decision-making by analyzing imaging, pathology, and genomic data simultaneously. As AI becomes more embedded in diagnostic processes, it will play a crucial role in enhancing the precision and scalability of personalized medicine.

• Growing Focus on Liquid Biopsies:

Liquid biopsies are gaining momentum as a less invasive and more convenient alternative to traditional tissue biopsies. This method involves analyzing circulating tumor DNA or other biomarkers in a blood sample, offering a real-time snapshot of a patient’s health. In companion diagnostics, liquid biopsies allow for frequent monitoring of treatment response and early detection of resistance mutations. This is particularly valuable in oncology, where disease progression needs to be closely monitored. Moreover, liquid biopsies facilitate easier testing in patients where tissue samples are difficult to obtain. Their growing acceptance across the healthcare ecosystem is set to transform how companion diagnostics are administered and tracked.

• Expansion into Non-Oncology Applications:

While oncology has been the primary focus for companion diagnostics, the market is gradually expanding into other therapeutic areas such as cardiovascular diseases, infectious diseases, and neurological disorders. As our understanding of disease biology deepens, biomarkers are being identified for a wider range of conditions. For example, companion diagnostics are being explored in Alzheimer’s disease to identify patients who may respond to amyloid-targeting drugs. Similarly, in infectious diseases like hepatitis C and COVID-19, diagnostics are helping predict treatment efficacy based on viral genotypes or host immune response. This diversification is opening new avenues for market players and reinforcing the importance of diagnostics in personalized treatment strategies.

Leading Companies Operating in the Companion Diagnostics Industry:

• Abbott Laboratories
• Agilent Technologies
• BioMerieux
• Danaher Corporation
• Roche Holding AG
• Myriad Genetics Inc.
• Siemens Healthcare
• Thermo Fisher Scientific Inc.

Companion Diagnostics Market Report Segmentation:

By Product & Service:

• Assays, Kits and Reagents
• Software and Services

Assays, kits, and reagents dominate the market due to their critical role in biomarker detection and enabling targeted therapies.

By Technology:

• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• In-situ Hybridization (ISH)
• Real-time PCR (RT-PCR)
• Gene Sequencing
• Others

Polymerase chain reaction (PCR) leads the segment owing to its widespread use in mutation detection and easy availability of diagnostic kits.

By Indication:

• Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Others
• Neurological Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

Cancer holds the largest share, driven by high disease prevalence and increasing approvals of companion diagnostics for oncology treatments.

By End User:

• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• Others

Pharmaceutical & biopharmaceutical companies account for the highest demand as they integrate companion diagnostics into drug development.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads the market, supported by advanced healthcare infrastructure, strong regulatory support, and high adoption of precision medicine.

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145